Morell-Molina E, Pardo-Yero H

Language: Spanish
References: 12
Page: 263-270
PDF size: 496.54 Kb.

ABSTRACT

Background: the urothelial carcinomas originate from the epithelium of mucous revetment of transitional type and constitute almost totality of the tumors of the excretory, high routes. The primary adenocarcinoma of the urinary tract, are extremely infrequent and they usually have an aggressive behavior, with a shaded prognosis.
Objective: to express the way of presenting a patient with urothelial carcinoma showing some aspects from the sicknesses.
Case report: a 70-years-old male patient, retired, inveterate smoker and with a history of ingesting coffee in large quantities, attended consultation for gross hematuria, lumbar pain, sometimes fixed, other times in the form of ureteral colic and fever of 39 degrees. The analytical study only showed altered lactic dehydrogenase rate. The imaging study with ultrasound showed hydronephrosis and enlarged right ilium with heterogeneous image of 2 cm in the kidney, at the level of the pelvic ureter junction, which was corroborated by computerized axial tomography. The rest of the examinations such as endoscopy, colonoscopy, and cystoscopy of different regions were all negative. Right nephroureterectomy was performed, and the patient is still asymptomatic.
Conclusions: the tumors of the upper urothelium are infrequent neoplasias, in the urinary tract an extraurological origin must be ruled out. The differential diagnosis must be made with the renal cell tumor or the bladder tumor.

REFERENCES

1. Ehdaie B, Shariat SF, Savage C, Coleman J, Dalbagn G. Postoperative Nomogram for Disease recurrence and cancer-specific death for upper tract urothelial carcinoma: comparison to American Joint Committee on Cancer Staging Classification. Urology J [Internet]. 2014 [citado 06 Mar 2020];11(2):[aprox. 9 p.]. Disponible en: Disponible en: http://www.urologyjournal.org/index.php/uj/article/view/1891/877.

2. Mc Conkey DJ, Choi W, Shen Y, Lee L, Porten S, Matin SF, et al. A Prognostic Gene expression signature in the molecular classification of chemotherapy-naïve urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: a phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer. Eur Urol [Internet]. 2016 [citado 06 Mar 2020];69(5):[aprox. 12 p.]. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4775435/ ..

3. Ross JS, Wang K, Al-Rohil RN, Nazeer T, Sheehan CE, Otto GA, et al. Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy. Modern Pathol [Internet]. 2014 [citado 22 Ago 2019];27(2):[aprox. 8 p.]. Disponible en: Disponible en: https://www.nature.com/articles/modpathol2013135.

4. Breen V, Kasabov N, Kamat AM, Jacobson E, Suttie JM, O'Sullivan PJ, et al. A holistic comparative analysis of diagnostic tests for urothelial carcinoma: a study of Cxbladder Detect, UroVision® FISH, NMP22® and cytology based on imputation of multiple datasets. BMC Med Res Methodol [Internet]. 2015 [citado 06 Mar 2020];15:[aprox. 12 p.]. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494166/pdf/12874_2015_Article_36.pdf.

5. Faltas BM, Prandi D, Tagawa ST, Molina AM, Nanus DM, Sternberg C, et al. Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nat Genet [Internet]. 2016 [citado 22 Ago 2019];48(12):[aprox. 12 p.]. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549141/ ..

6. Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester RJ, Burger M, et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2017 Update. Eur Urol [Internet]. 2018 [citado 06 Mar 2020];73(1):[aprox. 9 p.]. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/28867446.

7. Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester RJ, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. Eur Urology [Internet]. 2015 [citado 06 Mar 2020];68(5):[aprox. 11 p.]. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/26188393.

8. Nguyen D, Taheri D, Springer S, Cowan M, Guner G, Mendoza Rodriguez MA, et al. High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma. Virchows Arch [Internet]. 2016 Oct [citado 06 Mar 2020];469(4):[aprox. 6 p.]. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5561427/ ..

9. Cervantes-González ÓA, García-Nares S, Sánchez-Ramírez VW, Reyes-Arias Ó, Shuck-Bello CE. Carcinoma de uretra primario, reporte de caso y revisión de la literatura. Bol Col Mex Urol. Ene-Abr 2018;33(1):1-5..

10. Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, et al. Atezolizumab as fi rst-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet [Internet]. 2017 [citado 06 Mar 2020];389(10064):[aprox. 23 p.]. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568632/pdf/nihms896050.pdf.

11. Santana DJ, Serrano OF, Scarpetta LA. Carcinoma de cérvix estadio ib1 diagnosticado en el embarazo, reporte de un caso en el Hospital Militar Central, Bogotá [Internet]. Rev Colomb Obst Ginecol [Internet]. 2018 [citado 06 Mar 2020];69:[aprox. 3 p.]. Disponible en: Disponible en: http://search.ebscohost.com/login.aspx?direct=true&db=lth&AN=135653750&lang=es&site=ehost-live.

12. Albino Gonçalves L de A, Magalhães Câmara F, Dallacqua Santiago JH, Almeida Gonçalves L A de, Maciel Braga M, Saint-clair Pimentel Mafra R. Carcinoma sarcomatóide de bexiga em Paciente de 43 anos sem história prévia de Tabagismo e fatores predisponentes. Braz J Surg Clin Res. 2018;23(4):45-45..